For the first time since requiring drug makers to report pricing data about their diabetes medicines, Nevada officials plan to impose fines totaling more than $17 million on 21 companies for failing to supply information required by a controversial state law.

Earlier this week, the state Department of Health and Human Services wrote each of the drug makers that they face hundreds of thousands of dollars in penalties for not submitting required information, while several others will be fined for failing to meet a deadline. Each drug maker is entitled to an informal dispute resolution before the cases are referred to the state attorney general.

Unlock this article by subscribing to STAT Plus and enjoy your first 30 days free!


What is it?

STAT Plus is STAT's premium subscription service for in-depth biotech, pharma, policy, and life science coverage and analysis. Our award-winning team covers news on Wall Street, policy developments in Washington, early science breakthroughs and clinical trial results, and health care disruption in Silicon Valley and beyond.

What's included?

  • Daily reporting and analysis
  • The most comprehensive industry coverage from a powerhouse team of reporters
  • Subscriber-only newsletters
  • Daily newsletters to brief you on the most important industry news of the day
  • STAT+ Conversations
  • Weekly opportunities to engage with our reporters and leading industry experts in live video conversations
  • Exclusive industry events
  • Premium access to subscriber-only networking events around the country
  • The best reporters in the industry
  • The most trusted and well-connected newsroom in the health care industry
  • And much more
  • Exclusive interviews with industry leaders, profiles, and premium tools, like our CRISPR Trackr.
Sign up to receive a free weekly opinions recap from our community of experts.
Privacy Policy